

**STEROID DERIVATIVES I (1).**

**A SYNTHESIS OF 16-METHYLENE-17 $\alpha$ -ACETOXY-19-NOR-  
PROGESTERONE**

**V.Schwarz, (Mrs.) J.Zachova and K.Syhora**

**Research Institute for Pharmacy and Biochemistry  
Prague, Czechoslovakia**

(Received 14 March 1967)

In view of the well recognised enhancement of progestational activity by passing from the regular steroid series to the corresponding 19-nor-analogues (2,3), a synthesis of the title compound offered a logical extension of the broader program on 16-methylene derivatives initiated previously in this laboratory (4a-d, 5a,b).

Since the presence of the 16-methylene group might be expected to interfere with the removal of C-19 angular methyl group by the proposed standard method (6), the synthesis was started with 3 $\beta$ -acetoxy-16 $\beta$ -methyl-16 $\alpha$ ,17-oxidopregn-5-en-20-one (I) (4a), the oxido group of which might be expected to be satisfactorily void of reactivity in the steps under consideration, but readily convertible to the desired grouping. By addition of hypobromous acid, generated from N-bromoacetamide and perchloric acid in a mixture of aqueous dioxane and acetone,

the starting compound afforded crude 5 $\alpha$ -bromo-6 $\beta$ -hydroxy-derivative II, m.p.154-9 $^{\circ}$ , which was in turn treated with lead tetraacetate and iodine in benzene to give rise of 3 $\beta$ -acetoxy-5 $\alpha$ -bromo-16 $\beta$ -methyl-6 $\beta$ ,19;16 $\alpha$ ,17-dioxidopregnan-20-one (III), m.p.196-8 $^{\circ}$ ,  $[\alpha]_D + 5^{\circ}$ ,  $\nu$  1728,1703,1253,1035,920  $\text{cm}^{-1}$  (7). By reduction with zinc powder in boiling isopropyl-alcohol, the latter compound yielded 3 $\beta$ -acetoxy-19-hydroxy-16 $\beta$ -methyl-16 $\alpha$ ,17-oxidopregn-5-en-20-one (IVa), m.p.157-9 $^{\circ}$ ,  $[\alpha]_D - 20^{\circ}$ ,  $\nu$  3500,1725,1705,1356,1252,1031  $\text{cm}^{-1}$ , and, by the subsequent alkali hydrolysis, the corresponding 3,19-diol IVb, m.p.199-201 $^{\circ}$ ,  $[\alpha]_D - 31,6^{\circ}$ ,  $\nu$  3300,1700,1050  $\text{cm}^{-1}$ .

At this stage, an unequivocal evidence by independent synthesis seemed to be desirable in support of the structure IV because of an insufficient conclusiveness of available physico-chemical methods. To this goal, 3 $\beta$ ,19-dihydroxyandrost-5-en-17-one (Va) (8,9) was acetylated, and the corresponding diacetate Vb, m.p.108-109,5 $^{\circ}$ ,  $[\alpha]_D - 40^{\circ}$ (EtOH),  $\nu$  1735,1720,1405,1250,1031  $\text{cm}^{-1}$  was converted to 3 $\beta$ ,19-diacetoxy-17-cyano-androsta-5,16-diene (VII), m.p.133-4 $^{\circ}$ ,  $[\alpha]_D - 89^{\circ}$  (EtOH),  $\lambda_{\text{max}}$  218 nm ( $\log \epsilon$  3,88),  $\nu$  2215,1723,1590,1250,1031  $\text{cm}^{-1}$ , by addition of hydrocyanic acid and the subsequent dehydration of the mixture of epimeric cyano hydrines VI with phosphorus oxychloride in dry pyridine. By Grignard reaction of VII with methyl magnesium bromide in ether or benzene, 3 $\beta$ ,19-dihydroxypregna-5,16-dien-20-one (VIIIa), m.p.229-233 $^{\circ}$ ,  $[\alpha]_D - 37^{\circ}$  (EtOH),  $\lambda_{\text{max}}$  240 nm ( $\log \epsilon$  3,82),  $\nu$  3400,1650,1582,1040  $\text{cm}^{-1}$ , diacetate VIIIb, m.p.157,5-159 $^{\circ}$ ,  $[\alpha]_D - 70^{\circ}$ ,  $\nu$  1725,1655,1600,1250,1032  $\text{cm}^{-1}$  was formed. The diacetate VIIIb was treated

with diazomethane to give rise of the corresponding pyrazoline derivative IX, m.p.162-6°(decomp.),  $\nu$  1725,1708,1250,1032  $\text{cm}^{-1}$ , which was in turn pyrolysed to 3 $\beta$ ,19-diacetoxy-16-methylpregna-5,16-dien-20-one (X), m.p.146-152°,  $\lambda_{\text{max}}$  251 nm (log  $\epsilon$  3,94),  $\nu$  1725,1655,1432,1359,1250,1031  $\text{cm}^{-1}$ . On treatment with hydrogen peroxide in aqueous methanol in the presence of potassium hydroxide, the latter compound afforded a product, which was identical, in all respects, with the compound IVb obtained via the first route.

This intermediate was oxidised with aluminium isopropoxide and cyclohexanone to the corresponding 3-ketopregn-4-ene derivative XI, m.p.203-4°,  $[\alpha]_{\text{D}} + 125^{\circ}$ ,  $\lambda_{\text{max}}$  242 nm (log  $\epsilon$  4,16),  $\nu$  3610,3450,1700,1660,1620,1030  $\text{cm}^{-1}$ , and further, with Jones reagent (10), to 19-acid XII, m.p.175-7°(decomp.),  $[\alpha]_{\text{D}} + 171^{\circ}$ ,  $\lambda_{\text{max}}$  243 nm (log  $\epsilon$  4,02),  $\nu$  3200,1705,1695,1665,1620  $\text{cm}^{-1}$ . Decarboxylation of the latter in boiling pyridine gave rise to 16 $\beta$ -methyl-16 $\alpha$ ,17-oxido-19-norpregn-5(10)-ene-3,20-dione (XIII), m.p.125-7°,  $[\alpha]_{\text{D}} + 180^{\circ}$ ,  $\nu$  1708,1355  $\text{cm}^{-1}$ . By treatment with acetic anhydride in boiling toluene in the presence of sulphonylsalicylic acid, 16 $\alpha$ ,17-oxide ring opening to 17 $\alpha$ -acetoxy-16-methylene moiety (4c) was achieved along with a concomitant enol-acetylation and shift of 5(10)-double bond to afford 3,17 $\alpha$ -diacetoxy-16-methylene-19-norpregn-3,5-dien-20-one (XIV), m.p.186-9°,  $\lambda_{\text{max}}$  235 nm (log  $\epsilon$  4,21). On mild hydrolysis with methanolic potassium hydroxide in ethyl acetate, the 3-acetate group of XIV was removed selectively, and there was obtained the desired 16-methylene-17 $\alpha$ -acetoxy-19-norpregn-4-ene-3,20-dione XV, m.p.174-5°,  $[\alpha]_{\text{D}} -92^{\circ}$ ,  $\lambda_{\text{max}}$  240 nm (log  $\epsilon$  4,21),

$\nu$  1725, 1708, 1660, 1618, 1556, 1260, 892  $\text{cm}^{-1}$ .

All these physico-chemical properties are in full agreement with the proposed structure. Data on biological activity of the title compound and several intermediates will be published separately elsewhere.

#### REFERENCES

1. Communication II: Collection Czech.Chem.Comm., in press.
2. F.A.Kincl and R.I.Dorfman, Steroids 2, 521 (1963).
3. G.K.Suchowsky and G.Baldratti, J.Endocrinol. 30, 159 (1964).
- 4.a K.Syhora, Tetrahedron Letters 1960, No 17, 34; Collection Czech.Chem.Comm. 26, 107 (1961).  
 b R.Míčková and K.Syhora, Collection Czech.Chem.Comm. 29, 1163 (1964).  
 c K.Syhora and R.Mazáč, Collection Czech.Chem.Comm. 29, 2351 (1964).  
 d K.Syhora and R.Mazáč, Collection Czech.Chem.Comm. 31, 2768 (1966).
- 5.a Z.Čekan, M.Šeda, J.Mikulášková and K.Syhora, Steroids 4, 415 (1964).  
 b Z.Čekan, M.Šeda, J.Mikulášková and K.Syhora, Steroids 8, 205 (1966).
6. A.Bowers, R.Villotti, J.A.Edwards, E.Denot and O.Halpern, J.Am.Chem.Soc. 84, 3204 (1962).
7. Melting points (Boetius micro-stage) are uncorrected. The substances characterised by physical constants gave satisfactory elemental analyses. Optical rotation values refer to chloroform solution ( $c = \text{aprox.}1$ ), unless stated otherwise; UV- and IR-spectra were run in methanol and chloroform, respectively.
8. K.Tanabe, R.Takasaki, K.Sakai, R.Hayashi and Y.Morisawa, Chem.Pharm.Bull.(Tokyo) 10, 1126 (1962).

9. We express our thanks to Drs.A.D.Cross and J.A.Edwards

(Syntex Institute of Steroid Chemistry, Palo Alto, California, U.S.A.) for a generous gift of this material.

10. C.Djerassi, R.R.Engle and A.Bowers, J.Org.Chem. 21, 1547 (1956).

